CRVO logo

CervoMed Inc.

CRVO
Healthcare|Biotechnology|US
$1.42
-0.03 (-2.07%)
DCF Value
$0.80
Tangible Book / Share
$1.15
Cash / Share
$1.30

About

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Stock Price

-80.5%(1Y)
1M
-56.7%
3M
-50.5%
6M
-64.1%
YTD
-82.0%
1Y
-79.4%
3Y
-85.7%
5Y
-95.9%

Pipeline Summary

4 total trials
0
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
Completed: 3Active: 1

Active Trials (1)

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Phase 2Active
Enrollment: 20 participants

Key Facts

Market Cap$21.5M
Employees15 (+0% YoY)
CEOJohn J. Alam
IPO DateMay 23, 2008
Beta-4.30
52-Week Range$1.27 – $10
Avg Volume344,322
ExchangeNASDAQ
Websitecervomed.com

Ownership

Float63.6%
Shares Outstanding15.1M

Recent Insider Trades

Blackburn KellyAWARD
Oct 22, 202619,100 shares @ $2.24
De Rosch MarkAWARD
Oct 22, 202619,100 shares @ $2.24
Winton MatthewAWARD
Oct 22, 202619,100 shares @ $2.24
BOGER JOSHUA SBUY
Jun 11, 2026955,414 shares @ $3.14
BOGER JOSHUA SBUY
Jun 11, 2026955,414 shares @ $3.32

Peers

ACETAdicet Bio, Inc.
$28.6M
ADAGAdagene Inc.
$75.3M
FBIOFortress Biotech, Inc.
$61.7M
GANXGain Therapeutics, Inc.
$43.9M
LITSLite Strategy, Inc.
$31.0M
NRXPNRx Pharmaceuticals, Inc.
$103.0M
NTRBNutriband Inc.
$67.5M
OSTXOS Therapies Incorporated
$46.8M

Recent News

CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Oct 29, 2026 · globenewswire.com
CervoMed Shows Progress in Treating Rare Aphasia Condition
Oct 12, 2026 · benzinga.com
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright
Oct 5, 2026 · defenseworld.net
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
Oct 3, 2026 · defenseworld.net
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Sep 28, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:04 AM